Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process

Berndt Ernst R. (), Gottschalk Adrian H. B. (), Tomas Philipson and Strobeck Matthew W. ()
Additional contact information
Berndt Ernst R.: MIT and NBER
Gottschalk Adrian H. B.: Harvard-MIT Health Sciences and Technology Division
Strobeck Matthew W.: Harvard-MIT Health Sciences and Technolgoy Division

Forum for Health Economics & Policy, 2005, vol. 8, issue 1, 25

Abstract: Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors submitting applications to the FDA. While PDUFA mandated action or review times, its ultimate impacts on actual final drug approval times are unknown. We model and quantify the impact of PDUFA-I and II on drug approval times, since these approval dates are the ones most directly related to new medicines becoming available to benefit patients.In assessing the impacts of PDUFA on drug approval times, it is noteworthy that approval times were trending downwards at 1.7% percent per year prior to implementation of PDUFA. Assuming continuation of that time trend, approval times post-PDUFA would have fallen even in the absence of PDUFA. Our principal finding is that PDUFA accelerated this downward trend so that instead of a counterfactual 6% reduction in approval times from 24.2 to 20.4 months in absence of these acts between 1991 and 2002, there was an observed decline of about 42%, from 24.2 to 14.2 months, following implementation of PDUFA. Thus, of the total observed decline in approval times between 1991 and 2002, approximately two-thirds can be attributed to PDUFA. However, much of this impact occurred in the initial years between 1992 and 1997 (PDUFA-I) rather than during the subsequent 1997-2002 time frame (PDUFA-II). We discuss implications of these findings and how future research might quantify the social value of the observed acceleration in the FDA drug approvals.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://doi.org/10.2202/1558-9544.1013 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
Chapter: Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (2005)
Working Paper: Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (2004)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:fhecpo:v:8:y:2005:n:2

Ordering information: This journal article can be ordered from
https://www.degruyter.com/journal/key/fhep/html

DOI: 10.2202/1558-9544.1013

Access Statistics for this article

Forum for Health Economics & Policy is currently edited by Dana Goldman

More articles in Forum for Health Economics & Policy from De Gruyter
Bibliographic data for series maintained by Peter Golla ().